Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today

Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (BCRX -9.99%) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the day. That fall was far steeper than the 0.5% slip of the benchmark S&P 500 (^GSPC -0.50%).A mixed final quarter of 2024For the quarter, BioCryst managed to increase its revenue by 41% to $131.5 million. The company also narrowed its generally accepted ...